Keywords
Last Name

Jennifer R. Rider, ScD, MPH

TitleAssistant Professor
InstitutionBoston University School of Public Health
DepartmentEpidemiology
Address715 Albany Street, T317E
Boston MA 02118
Phone(617) 638-5035
 Awards and Honors

Start-EndDescription
2005American Urological Association: Travel Award
2006American Association of Cancer Research: Scholar-in-Training Award
2007Harvard College: Certificate of Distinction in Teaching
2008-2009American Association of Cancer Research: Scholar-in-Training Award
2009-2015National Cancer Institute: NIH Loan Repayment Program Recipient
2011-2013Harvard School of Public Health: Teaching Commendation
2012Prostate Cancer Foundation, American Urological Association Annual Meeting: First Place Abstract
2012American Urological Association, AUA Annual Meeting: Best Poster in Session
2012-2015Prostate Cancer Foundation: Michael and Lori Milken-PCF Young Investigator Award
2013Harvard Medical School: The Eleanor and Miles Shore 50th Anniversary Fellowship Program for Scholars in Medicine
2013European Urology: Best Clinical Research Paper of 2013
 Research Expertise & Professional Interests
My primary research interests involve using population-based studies of genetic, circulating, and tumor biomarkers to investigate the role of inflammation and infections in carcinogenesis. I also have a general interest in prostate cancer epidemiology and the identification of patient and tumor characteristics that could reduce overdiagnosis and overtreatment. Collaborating with research pathologists, urologists, medical oncologists, molecular biologists, immunologists, virologists, and bioinformaticists, I have utilized data from a large Swedish population-based studies (CaPS and PCBaSe) and a Swedish randomized trial (SPCG-4), Swedish clinical cohorts, the Physicians’ Health Study, and the Health Professionals Follow-up Study.

Through collaborations with Swedish and US-based investigators, I am expanding my research focus to study the role of infections on various malignancies. I am involved in ongoing studies of HPV infection in penile carcinoma and tumors of the head and neck. Moreover, I am pursuing projects that investigate malignancies in HIV-infected populations, including a study to shed light on the lower incidence of prostate cancer in HIV-positive compared to HIV-negative men.

 Self-Described Keywords
  • epidemiology
  • prostate cancer
  • infection-associated cancers
  • cancer etiology
  • biomarkers
 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Zareba P, Flavin R, Isikbay M, Rider JR, Gerke TA, Finn S, Pettersson A, Giunchi F, Unger RH, Tinianow AM, Andersson SO, Andrén O, Fall K, Fiorentino M, Mucci LA. Perineural invasion and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev. 2017 Jan 06. PMID: 28062398.
    View in: PubMed
  2. Wilson KM, Markt SC, Fang F, Nordenvall C, Rider JR, Ye W, Adami HO, Stattin P, Nyrén O, Mucci LA. Snus use, smoking and survival among prostate cancer patients. Int J Cancer. 2016 Dec 15; 139(12):2753-2759. PMID: 27582277.
    View in: PubMed
  3. Markt SC, Nuttall E, Turman C, Sinnott J, Rimm EB, Ecsedy E, Unger RH, Fall K, Finn S, Jensen MK, Rider JR, Kraft P, Mucci LA. Sniffing out significant "Pee values": genome wide association study of asparagus anosmia. BMJ. 2016 Dec 13; 355:i6071. PMID: 27965198.
    View in: PubMed
  4. Kelly RS, Sinnott JA, Rider JR, Ebot EM, Gerke T, Bowden M, Pettersson A, Loda M, Sesso HD, Kantoff PW, Martin NE, Giovannucci EL, Tyekucheva S, Heiden MV, Mucci LA. The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study. Cancer Metab. 2016; 4:22. PMID: 27980733.
    View in: PubMed
  5. Sinnott JA, Peisch SF, Tyekucheva S, Gerke T, Lis R, Rider JR, Fiorentino M, Stampfer MJ, Mucci LA, Loda M, Penney KL. Prognostic Utility of a New mRNA Expression Signature of Gleason Score. Clin Cancer Res. 2017 Jan 01; 23(1):81-87. PMID: 27663590.
    View in: PubMed
  6. Sigurdardottir LG, Markt SC, Sigurdsson S, Aspelund T, Fall K, Schernhammer E, Rider JR, Launer L, Harris T, Stampfer MJ, Gudnason V, Czeisler CA, Lockley SW, Valdimarsdottir UA, Mucci LA. Pineal Gland Volume Assessed by MRI and Its Correlation with 6-Sulfatoxymelatonin Levels among Older Men. J Biol Rhythms. 2016 Oct; 31(5):461-9. PMID: 27449477.
    View in: PubMed
  7. Yang M, Zu K, Mucci LA, Rider JR, Fiorentino M, Clinton SK, Loda M, Stampfer MJ, Giovannucci E. Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade. Cancer Causes Control. 2016 Aug; 27(8):1043-7. PMID: 27379990.
    View in: PubMed
  8. Davidsson S, Mölling P, Rider JR, Unemo M, Karlsson MG, Carlsson J, Andersson SO, Elgh F, Söderquist B, Andrén O. Erratum to: Frequency and typing of Propionibacterium acnes in prostate tissue obtained from men with and without prostate cancer. Infect Agent Cancer. 2016; 11:36. PMID: 27335583.
    View in: PubMed
  9. Stopsack KH, Gerke TA, Sinnott JA, Penney KL, Tyekucheva S, Sesso HD, Andersson SO, Andrén O, Cerhan JR, Giovannucci EL, Mucci LA, Rider JR. Cholesterol Metabolism and Prostate Cancer Lethality. Cancer Res. 2016 Aug 15; 76(16):4785-90. PMID: 27325648.
    View in: PubMed
  10. Rider JR, Wilson KM, Mucci LA, Giovannucci EL. Reply to Cédric Annweiler, Pierre Bigot, and Spyridon N. Karras' Letter to the Editor re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer A. Sinnott, Rachel S. Kelly, Lorelei A. Muccia, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol 2016;70:974-82. Eur Urol. 2017 Jan; 71(1):e18. PMID: 27317088.
    View in: PubMed
  11. Rider JR. Lead Time, Like Trains and Tides, Stops for No One. Eur Urol. 2017 Feb; 71(2):202-203. PMID: 27311361.
    View in: PubMed
  12. Davidsson S, Mölling P, Rider JR, Unemo M, Karlsson MG, Carlsson J, Andersson SO, Elgh F, Söderquis B, Andrén O. Frequency and typing of Propionibacterium acnes in prostate tissue obtained from men with and without prostate cancer. Infect Agent Cancer. 2016; 11:26. PMID: 27284286.
    View in: PubMed
  13. Rider JR, Wilson KM, Sinnott JA, Kelly RS, Mucci LA, Giovannucci EL. Reply to Herney Andrés García-Perdomo and Ramiro Manzano Nunez's Letter to the Editor Re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer M. Sinnott, Rachel S. Kelly, Lorelei A. Mucci, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol 2016;70:974-82: Looking Deeper: P-hacking and Some Other Bias. Eur Urol. 2016 Dec; 70(6):e156-e157. PMID: 27156131.
    View in: PubMed
  14. Börnigen D, Tyekucheva S, Wang X, Rider JR, Lee GS, Mucci LA, Sweeney C, Huttenhower C. Computational Reconstruction of NF?B Pathway Interaction Mechanisms during Prostate Cancer. PLoS Comput Biol. 2016 Apr; 12(4):e1004820. PMID: 27078000.
    View in: PubMed
  15. Rider JR, Wilson KM, Sinnott JA, Kelly RS, Mucci LA, Giovannucci EL. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol. 2016 Dec; 70(6):974-982. PMID: 27033442.
    View in: PubMed
  16. Shui IM, Kolb S, Hanson C, Sutcliffe S, Rider JR, Stanford JL. Trichomonas vaginalis infection and risk of advanced prostate cancer. Prostate. 2016 May; 76(7):620-3. PMID: 26818005.
    View in: PubMed
  17. Graff RE, Pettersson A, Lis RT, Ahearn TU, Markt SC, Wilson KM, Rider JR, Fiorentino M, Finn S, Kenfield SA, Loda M, Giovannucci EL, Rosner B, Mucci LA. Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. Am J Clin Nutr. 2016 Mar; 103(3):851-60. PMID: 26817504.
    View in: PubMed
  18. Thorgeirsson T, Jordahl KM, Flavin R, Epstein MM, Fiorentino M, Andersson SO, Andren O, Rider JR, Mosquera JM, Ingoldsby H, Fall K, Tryggvadottir L, Mucci LA. Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort. Carcinogenesis. 2016 Mar; 37(3):262-8. PMID: 26775038.
    View in: PubMed
  19. Markt SC, Flynn-Evans EE, Valdimarsdottir UA, Sigurdardottir LG, Tamimi RM, Batista JL, Haneuse S, Lockley SW, Stampfer M, Wilson KM, Czeisler CA, Rider JR, Mucci LA. Sleep Duration and Disruption and Prostate Cancer Risk: a 23-Year Prospective Study. Cancer Epidemiol Biomarkers Prev. 2016 Feb; 25(2):302-8. PMID: 26677208.
    View in: PubMed
  20. Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. J Natl Cancer Inst. 2016 Feb; 108(2). PMID: 26615022.
    View in: PubMed
  21. Montgomery S, Brus O, Hiyoshi A, Cao Y, Rider J, Fall K. Childhood exposures among mothers and Hodgkin's lymphoma in offspring. Cancer Epidemiol. 2015 Dec; 39(6):1006-9. PMID: 26590334.
    View in: PubMed
  22. Rider JR. Trouble in Paradise: Unmeasured Confounding in Registry-based Studies of Etiologic Factors. Eur Urol. 2016 May; 69(5):883-4. PMID: 26559127.
    View in: PubMed
  23. Stopsack KH, Ziehr DR, Rider JR, Giovannucci EL. Metformin and prostate cancer mortality: a meta-analysis. Cancer Causes Control. 2016 Jan; 27(1):105-13. PMID: 26537119.
    View in: PubMed
  24. Hurley PJ, Sundi D, Shinder B, Simons BW, Hughes RM, Miller RM, Benzon B, Faraj SF, Netto GJ, Vergara IA, Erho N, Davicioni E, Karnes RJ, Yan G, Ewing C, Isaacs SD, Berman DM, Rider JR, Jordahl KM, Mucci LA, Huang J, An SS, Park BH, Isaacs WB, Marchionni L, Ross AE, Schaeffer EM. Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer. Clin Cancer Res. 2016 Jan 15; 22(2):448-58. PMID: 26446945.
    View in: PubMed
  25. Dryden-Peterson S, Medhin H, Kebabonye-Pusoentsi M, Seage GR, Suneja G, Kayembe MK, Mmalane M, Rebbeck T, Rider JR, Essex M, Lockman S. Correction: Cancer Incidence following Expansion of HIV Treatment in Botswana. PLoS One. 2015; 10(9):e0138742. PMID: 26376079.
    View in: PubMed
  26. Dryden-Peterson S, Medhin H, Kebabonye-Pusoentsi M, Seage GR, Suneja G, Kayembe MK, Mmalane M, Rebbeck T, Rider JR, Essex M, Lockman S. Cancer Incidence following Expansion of HIV Treatment in Botswana. PLoS One. 2015; 10(8):e0135602. PMID: 26267867.
    View in: PubMed
  27. Sinnott JA, Rider JR, Carlsson J, Gerke T, Tyekucheva S, Penney KL, Sesso HD, Loda M, Fall K, Stampfer MJ, Mucci LA, Pawitan Y, Andersson SO, Andrén O. Molecular differences in transition zone and peripheral zone prostate tumors. Carcinogenesis. 2015 Jun; 36(6):632-8. PMID: 25870172.
    View in: PubMed
  28. Rider JR, Fiorentino M, Kelly R, Gerke T, Jordahl K, Sinnott JA, Giovannucci EL, Loda M, Mucci LA, Finn S. Tumor expression of adiponectin receptor 2 and lethal prostate cancer. Carcinogenesis. 2015 Jun; 36(6):639-47. PMID: 25863129.
    View in: PubMed
  29. Graff RE, Pettersson A, Lis RT, DuPre N, Jordahl KM, Nuttall E, Rider JR, Fiorentino M, Sesso HD, Kenfield SA, Loda M, Giovannucci EL, Rosner B, Nguyen PL, Sweeney CJ, Mucci LA. The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer. Prostate. 2015 Jun 15; 75(9):897-906. PMID: 25728532.
    View in: PubMed
  30. Markt SC, Valdimarsdottir UA, Shui IM, Sigurdardottir LG, Rider JR, Tamimi RM, Batista JL, Haneuse S, Flynn-Evans E, Lockley SW, Czeisler CA, Stampfer MJ, Launer L, Harris T, Smith AV, Gudnason V, Lindstrom S, Kraft P, Mucci LA. Circadian clock genes and risk of fatal prostate cancer. Cancer Causes Control. 2015 Jan; 26(1):25-33. PMID: 25388799.
    View in: PubMed
  31. Siddiqui MM, Wilson KM, Epstein MM, Rider JR, Martin NE, Stampfer MJ, Giovannucci EL, Mucci LA. Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study. J Clin Oncol. 2014 Sep 20; 32(27):3033-8. PMID: 25002716.
    View in: PubMed
  32. Sigurdardottir LG, Markt SC, Rider JR, Haneuse S, Fall K, Schernhammer ES, Tamimi RM, Flynn-Evans E, Batista JL, Launer L, Harris T, Aspelund T, Stampfer MJ, Gudnason V, Czeisler CA, Lockley SW, Valdimarsdottir UA, Mucci LA. Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men. Eur Urol. 2015 Feb; 67(2):191-4. PMID: 25107635.
    View in: PubMed
  33. Markt SC, Rider JR, Penney KL, Schumacher FR, Epstein MM, Fall K, Sesso HD, Stampfer MJ, Mucci LA. Genetic variation across C-reactive protein and risk of prostate cancer. Prostate. 2014 Jul; 74(10):1034-42. PMID: 24844401.
    View in: PubMed
  34. Flavin R, Pettersson A, Hendrickson WK, Fiorentino M, Finn S, Kunz L, Judson GL, Lis R, Bailey D, Fiore C, Nuttall E, Martin NE, Stack E, Penney KL, Rider JR, Sinnott J, Sweeney C, Sesso HD, Fall K, Giovannucci E, Kantoff P, Stampfer M, Loda M, Mucci LA. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res. 2014 Sep 15; 20(18):4904-11. PMID: 24687926.
    View in: PubMed
  35. Sharma J, Gray KP, Harshman LC, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ. Elevated IL-8, TNF-a, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate. 2014 Jun; 74(8):820-8. PMID: 24668612.
    View in: PubMed
  36. Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, Nordling S, Häggman M, Andersson SO, Spångberg A, Andrén O, Palmgren J, Steineck G, Adami HO, Johansson JE. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014 Mar 6; 370(10):932-42. PMID: 24597866.
    View in: PubMed
  37. Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, Fiorentino M, Finn S, Graff RE, Penney KL, Rider JR, Nuttall EJ, Martin NE, Sesso HD, Pollak M, Stampfer MJ, Kantoff PW, Giovannucci EL, Loda M, Mucci LA. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst. 2013 Dec 18; 105(24):1881-90. PMID: 24292212.
    View in: PubMed
  38. Sharma J, Gray KP, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ. Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Prostate. 2014 Feb; 74(3):225-34. PMID: 24132762.
    View in: PubMed
  39. Penney KL, Stampfer MJ, Jahn JL, Sinnott JA, Flavin R, Rider JR, Finn S, Giovannucci E, Sesso HD, Loda M, Mucci LA, Fiorentino M. Gleason grade progression is uncommon. Cancer Res. 2013 Aug 15; 73(16):5163-8. PMID: 23946472.
    View in: PubMed
  40. Sigurdardottir LG, Valdimarsdottir UA, Mucci LA, Fall K, Rider JR, Schernhammer E, Czeisler CA, Launer L, Harris T, Stampfer MJ, Gudnason V, Lockley SW. Sleep disruption among older men and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2013 May; 22(5):872-9. PMID: 23652374.
    View in: PubMed
  41. Bill-Axelson A, Garmo H, Holmberg L, Johansson JE, Adami HO, Steineck G, Johansson E, Rider JR. Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial. Eur Urol. 2013 Dec; 64(6):920-8. PMID: 23465517.
    View in: PubMed
  42. Schoenfeld JD, Margalit DN, Kasperzyk JL, Shui IM, Rider JR, Epstein MM, Meisner A, Kenfield SA, Martin NE, Nguyen PL, Kantoff PW, Giovannucci EL, Stampfer MJ, Mucci LA. A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer. Clin Cancer Res. 2013 Mar 15; 19(6):1612-9. PMID: 23382116.
    View in: PubMed
  43. Chen YC, Huang YL, Platz EA, Alderete JF, Zheng L, Rider JR, Kraft P, Giovannucci E, Sutcliffe S. Prospective study of effect modification by Toll-like receptor 4 variation on the association between Trichomonas vaginalis serostatus and prostate cancer. Cancer Causes Control. 2013 Jan; 24(1):175-80. PMID: 23179660.
    View in: PubMed
  44. Popiolek M, Rider JR, Andrén O, Andersson SO, Holmberg L, Adami HO, Johansson JE. Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol. 2013 Mar; 63(3):428-35. PMID: 23084329.
    View in: PubMed
  45. Davidsson S, Ohlson AL, Andersson SO, Fall K, Meisner A, Fiorentino M, Andrén O, Rider JR. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer. Mod Pathol. 2013 Mar; 26(3):448-55. PMID: 23041830.
    View in: PubMed
  46. Rider JR, Sandin F, Andrén O, Wiklund P, Hugosson J, Stattin P. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol. 2013 Jan; 63(1):88-96. PMID: 22902040.
    View in: PubMed
  47. Epstein MM, Edgren G, Rider JR, Mucci LA, Adami HO. Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst. 2012 Sep 5; 104(17):1335-42. PMID: 22835388.
    View in: PubMed
  48. Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon AH, Suppan C, Flavin R, Sesso HD, Rider JR, Sweeney C, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci EL, Ding EL, Loda M, Mucci LA. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1497-509. PMID: 22736790.
    View in: PubMed
  49. Epstein MM, Andrén O, Kasperzyk JL, Shui IM, Penney KL, Fall K, Rider JR, Stampfer MJ, Andersson SO, Giovannucci E, Mucci LA. Seasonal variation in expression of markers in the vitamin D pathway in prostate tissue. Cancer Causes Control. 2012 Aug; 23(8):1359-66. PMID: 22710747.
    View in: PubMed
  50. Sigurdardottir LG, Valdimarsdottir UA, Fall K, Rider JR, Lockley SW, Schernhammer E, Mucci LA. Circadian disruption, sleep loss, and prostate cancer risk: a systematic review of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2012 Jul; 21(7):1002-11. PMID: 22564869.
    View in: PubMed
  51. Dhillon PK, Penney KL, Schumacher F, Rider JR, Sesso HD, Pollak M, Fiorentino M, Finn S, Loda M, Rifai N, Mucci LA, Giovannucci E, Stampfer MJ, Ma J. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec; 20(12):2618-27. PMID: 21960694.
    View in: PubMed
  52. Davidsson S, Fiorentino M, Andrén O, Fang F, Mucci LA, Varenhorst E, Fall K, Rider JR. Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011 Oct; 20(10):2280-7. PMID: 21953116.
    View in: PubMed
  53. Wilson KM, Kasperzyk JL, Rider JR, Kenfield S, van Dam RM, Stampfer MJ, Giovannucci E, Mucci LA. Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. J Natl Cancer Inst. 2011 Jun 8; 103(11):876-84. PMID: 21586702.
    View in: PubMed
  54. Shui IM, Stark JR, Penney KL, Schumacher FR, Epstein MM, Pitt MJ, Stampfer MJ, Tamimi RM, Lindstrom S, Sesso HD, Fall K, Ma J, Kraft P, Giovannucci E, Mucci LA. Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality. Prostate. 2012 Feb 1; 72(2):209-16. PMID: 21563195.
    View in: PubMed
  55. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Steineck G, Adami HO, Johansson JE. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011 May 5; 364(18):1708-17. PMID: 21542742.
    View in: PubMed
  56. Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y, Kraft P, Stark JR, Fiorentino M, Perner S, Finn S, Calza S, Flavin R, Freedman ML, Setlur S, Sesso HD, Andersson SO, Martin N, Kantoff PW, Johansson JE, Adami HO, Rubin MA, Loda M, Golub TR, Andrén O, Stampfer MJ, Mucci LA. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol. 2011 Jun 10; 29(17):2391-6. PMID: 21537050.
    View in: PubMed
  57. Andersson SO, Andrén O, Lyth J, Stark JR, Henriksson M, Adami HO, Carlsson P, Johansson JE. Managing localized prostate cancer by radical prostatectomy or watchful waiting: Cost analysis of a randomized trial (SPCG-4). Scand J Urol Nephrol. 2011 Apr; 45(3):177-83. PMID: 21265595.
    View in: PubMed
  58. Kirrander P, Kolaric A, Helenius G, Windahl T, Andrén O, Stark JR, Lillsunde-Larsson G, Elgh F, Karlsson M. Human papillomavirus prevalence, distribution and correlation to histopathological parameters in a large Swedish cohort of men with penile carcinoma. BJU Int. 2011 Aug; 108(3):355-9. PMID: 21044240.
    View in: PubMed
  59. Meyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M, Fiorentino M, Finn S, Flavin RJ, Kurth T, Price AL, Giovannucci EL, Fall K, Stampfer MJ, Ma J, Mucci LA. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis. 2010 Sep; 31(9):1597-603. PMID: 20576793.
    View in: PubMed
  60. Fiorentino M, Judson G, Penney K, Flavin R, Stark J, Fiore C, Fall K, Martin N, Ma J, Sinnott J, Giovannucci E, Stampfer M, Sesso HD, Kantoff PW, Finn S, Loda M, Mucci L. Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res. 2010 Apr 15; 70(8):3136-9. PMID: 20388772.
    View in: PubMed
  61. Mucci LA, Stark JR, Pollak MN, Li H, Kurth T, Stampfer MJ, Ma J. Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev. 2010 Feb; 19(2):484-91. PMID: 20142246.
    View in: PubMed
  62. Stark JR, Mucci L, Rothman KJ, Adami HO. Screening for prostate cancer remains controversial. BMJ. 2009; 339:b3601. PMID: 19778971.
    View in: PubMed
  63. Stark JR, Judson G, Alderete JF, Mundodi V, Kucknoor AS, Giovannucci EL, Platz EA, Sutcliffe S, Fall K, Kurth T, Ma J, Stampfer MJ, Mucci LA. Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study. J Natl Cancer Inst. 2009 Oct 21; 101(20):1406-11. PMID: 19741211.
    View in: PubMed
  64. Mucci LA, Stark JR, Figg WD, Schumacher F, Li H, Abe M, Hennessy K, Stampfer MJ, Gaziano JM, Ma J, Kantoff PW. Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study. Int J Cancer. 2009 Sep 1; 125(5):1143-6. PMID: 19431146.
    View in: PubMed
  65. Stark JR, Li H, Kraft P, Kurth T, Giovannucci EL, Stampfer MJ, Ma J, Mucci LA. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer. 2009 Jun 1; 124(11):2683-9. PMID: 19189403.
    View in: PubMed
  66. Stark JR, Wiklund F, Grönberg H, Schumacher F, Sinnott JA, Stampfer MJ, Mucci LA, Kraft P. Toll-like receptor signaling pathway variants and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev. 2009 Jun; 18(6):1859-63. PMID: 19505919.
    View in: PubMed
  67. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 2009 Jul 20; 27(21):3459-64. PMID: 19433685.
    View in: PubMed
  68. Fall K, Stark JR, Mucci LA, Chan J, Stampfer MJ, Kurth T, Febbo PG, Kantoff P, Ma J. No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk. Prostate. 2008 Sep 15; 68(13):1416-20. PMID: 18615538.
    View in: PubMed
  69. Mucci LA, Pawitan Y, Demichelis F, Fall K, Stark JR, Adami HO, Andersson SO, Andrén O, Eisenstein A, Holmberg L, Huang W, Kantoff PW, Kim R, Perner S, Stampfer MJ, Johansson JE, Rubin MA. Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol Biomarkers Prev. 2008 Jul; 17(7):1682-8. PMID: 18583469.
    View in: PubMed
  70. LaPelle N, Costanza ME, Luckmann R, Rosal MC, White MJ, Stark JR. Staging mammography nonadherent women: a qualitative study. J Cancer Educ. 2008; 23(2):114-21. PMID: 18569247.
    View in: PubMed
  71. Mucci LA, Pawitan Y, Demichelis F, Fall K, Stark JR, Adami HO, Andersson SO, Andrén O, Eisenstein AS, Holmberg L, Huang W, Kantoff PW, Perner S, Stampfer MJ, Johansson JE, Rubin MA. Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort. Cancer Epidemiol Biomarkers Prev. 2008 Jan; 17(1):249-51. PMID: 18199732.
    View in: PubMed
  72. Costanza ME, Luckmann R, Stoddard AM, White MJ, Stark JR, Avrunin JS, Rosal MC, Clemow L. Using tailored telephone counseling to accelerate the adoption of colorectal cancer screening. Cancer Detect Prev. 2007; 31(3):191-8. PMID: 17646058.
    View in: PubMed
  73. Stark JR, Bertone-Johnson ER, Costanza ME, Stoddard AM. Factors associated with colorectal cancer risk perception: the role of polyps and family history. Health Educ Res. 2006 Oct; 21(5):740-9. PMID: 16801376.
    View in: PubMed
  74. Costanza ME, Luckmann R, Stoddard AM, Avrunin JS, White MJ, Stark JR, Clemow L, Rosal MC. Applying a stage model of behavior change to colon cancer screening. Prev Med. 2005 Sep-Oct; 41(3-4):707-19. PMID: 16171854.
    View in: PubMed
  75. White MJ, Stark JR, Luckmann R, Rosal MC, Clemow L, Costanza ME. Implementing a computer-assisted telephone interview (CATI) system to increase colorectal cancer screening: a process evaluation. Patient Educ Couns. 2006 Jun; 61(3):419-28. PMID: 15993558.
    View in: PubMed
Jennifer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department